Company Description
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.
The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.
It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.
In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications.
Sunshine The company is based in Fort Lauderdale, Florida.
| Country | United States |
| Founded | 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Steve Slilaty |
Contact Details
Address: 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale, Florida 33301 United States | |
| Phone | 954 330 0684 |
| Website | sunshinebiopharma.com |
Stock Details
| Ticker Symbol | SBFM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1402328 |
| CUSIP Number | 867781809 |
| ISIN Number | US8677818093 |
| Employer ID | 20-5566275 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steve N. Slilaty Ph.D. | Chairman, President and Chief Executive Officer |
| Camille Sebaaly | Chief Financial Officer, Secretary and Director |
| Michel Roy | Chief Commercial Officer |
| Malek Chamoun | Chief Development Officer |
| Robert G. Ferreira | President of Sunshine Bio Investments Inc |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | PRE 14C | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 11, 2026 | 8-K | Current Report |
| Sep 8, 2026 | EFFECT | Notice of Effectiveness |
| Sep 8, 2026 | 424B3 | Prospectus |
| Aug 28, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | SCHEDULE 13G/A | Filing |